IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

Molenaar, R. J., Radivoyevitch, T., Nagata, Y., Khurshed, M., Przychodzen, B., Makishima, H., Xu, M., Bleeker, F. E., Wilmink, J. W., Carraway, H. E., Mukherjee, S., Sekeres, M. A., van Noorden, C. J. F., Maciejewski, J. P.
The American Association for Cancer Research (AACR)
Published 2018